Digest Network Come funziona
Network
/
Società
Ce
Non verificato

Cellworks Group Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

8 comunicati stampa

Guarda tutti i comunicati
08/09/2025
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Cellworks Unveils a Breakthrough in Predicting Chemo-Immunotherapy Benefit for Patients with Metastatic NSCLC
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
08/09/2025
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Eventi
Industria
Cellworks Study Reveals Tumor Microenvironment and TLS Dynamics Together Predict Patient-Level Immunotherapy Response in NSCLC
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
29/04/2025
Eventi
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Cellworks’ Study Predicts Immune Checkpoint Inhibitor Resistance in Patients with High Microsatellite Instability
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
12/11/2024
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Cellworks Enhances TRI with Personalized Tumor Microenvironment Modeling to Predict Overall Survival in NSCLC Patients Receiving Immunotherapy
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
16/09/2024
Eventi
Fiere
Industria
Scienza
Biotecnologia
Medicina - Varie
Farmaceutica
Salute
Oncologia
Cellworks Biosimulation Combined with Tumor Microenvironment Modeling Enhances Predictions of IO Response in NSCLC Patients
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
16/09/2024
Eventi
Fiere
Industria
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Cellworks Biosimulation Predicts PARPi Benefit in Patients with Ovarian, Pancreatic, Prostate and Triple-Negative Breast Cancers
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
11/09/2024
Industria
Software
Scienza
Farmaceutica
Oncologia
Attrezzature medico-sanitarie
Tecnica
Biotecnologia
Medicina - Varie
Salute
Cellworks Biosimulation Identifies which NSCLC Patients will Benefit from Combining Chemotherapy with Immunotherapy
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0
09/09/2024
Industria
Biotecnologia
Salute
Farmaceutica
Oncologia
Cellworks Biosimulation Predicts Chemotherapy Benefit in Osimertinib-treated NSCLC Patients with EGFR Mutations
Fonte
Cellworks Group Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0